利拉利汀是由Boehringer Ingelheim開發(fā)的用于治療2型糖尿病的二肽基肽酶-4抑制劑。
(2S,3S)-2,3-Dihydroxysuccinic acid
Piperidin-3-amine
(R)-Piperidin-3-amine dihydrochloride
(R)-tert-Butyl (1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate
1-Bromo-2-butyne
8-Bromo-7-(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione
(R)-8-(3-Aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione
(R)-tert-Butyl piperidin-3-ylcarbamate
8-Bromo-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione
2-(Chloromethyl)-4-methylquinazoline
8-Bromo-3-methyl-1H-purine-2,6(3H,7H)-dione
(R)-2-(Piperidin-3-yl)isoindoline-1,3-dione (2S,3S)-2,3-dihydroxysuccinate
(R)-EThylpiperidine-3-carboxylate(2R,3R)-2,3-dihydroxysuccinate
(R)-7-(But-2-ynyl)-8-(3-(1,3-dioxoisoindolin-2-yl)piperidin-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione
